` BML (Biomed Lublin Wytwornia Surowic i Szczepionek SA) vs WIG20 Comparison - Alpha Spread

B
BML
vs
W
WIG20

Over the past 12 months, BML has underperformed WIG20, delivering a return of 0% compared to the WIG20's +36% growth.

Stocks Performance
BML vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BML vs WIG20

Performance Gap Between BML and WIG20
HIDDEN
Show

Performance By Year
BML vs WIG20

Loading
BML
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Biomed Lublin Wytwornia Surowic i Szczepionek SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Biomed Lublin Wytwornia Surowic i Szczepionek SA
Glance View

Market Cap
378.5m PLN
Industry
Biotechnology

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 223 full-time employees. The company went IPO on 2011-07-29.

BML Intrinsic Value
Not Available
Back to Top